The allosteric mTORC1 inhibitor rapamycin has been shown to revert Akt-dependent early prostate intraepithelial neoplasia (PIN) in young mice through regulation of apoptotic and HIF-1-dependent pathways[93]. Here, AKT1 is linked to prostate intraepithelial neoplasia.